ABT-869 Trial for Advanced RCC

November 1, 2007

An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib.

This trial is an Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib (Sutent)

Clinical trial locations include many in the U.S. and at least one site in Canada (British Columbia). For further details, see this clinical trial description.

 

Back to news listings
comments powered by Disqus